



(11) **EP 1 658 772 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

Note: Bibliography reflects the latest situation

(15) Correction information:

Corrected version no 1 (W1 A2)
INID code(s) 71

(51) Int Cl.:

A01N 63/00 ^(2006.01) **A61K 39/385** ^(2006.01)
A61K 39/00 ^(2006.01) **A61K 47/48** ^(2006.01)

(48) Corrigendum issued on:

10.01.2007 Bulletin 2007/02

(43) Date of publication:

24.05.2006 Bulletin 2006/21

(21) Application number: **05112065.7**

(22) Date of filing: **17.01.1996**

(84) Designated Contracting States:

**AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE**

(30) Priority: **17.01.1995 US 374159**

29.12.1995 US 578171

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:

03004479.6 / 1 323 346

96903522.9 / 0 805 628

(71) Applicants:

- **THE BRIGHAM AND WOMEN'S HOSPITAL, INC.**
Boston, MA 02115 (US)
- **BRANDEIS UNIVERSITY**
Waltham, MA 02254 (US)

(72) Inventors:

- **Blumberg, Richard S.**
Chestnut Hill,
Massachusetts 02167 (US)
- **Simister, Neil E.**
Wellesley,
Massachusetts 02482 (US)
- **Lencer, Wayne I.**
Jamaica Plain,
Massachusetts 02130 (US)

(74) Representative: **Cowley, Catherine Mary et al**

Venner Shipley LLP,
20 Little Britain
London EC1A 7DH (GB)

Remarks:

This application was filed on 13 - 12 - 2005 as a
divisional application to the application mentioned
under INID code 62.

(54) **Receptor specific transepithelial transport of immunogens**

(57) Methods and products for modulating an immune response are provided. Pharmaceutical preparations contain a conjugate of an antigen and an FcRn binding partner. The conjugates are administered to mammals in effective amounts to modulate the immune sys-

tem by stimulating the immune response against the antigen or tolerizing the immune system to the antigen. The antigen may be characteristic of a pathogen, of an autoimmune disease, of an allergen or of a tumor.

EP 1 658 772 A8